Kyleena (Levonorgestrel)

Levonorgestrel released from the intrauterine system acts locally within the uterus. It thickens cervical mucus, creating a barrier that hinders sperm entry, suppresses the growth of the endometrium, and impairs sperm motility and function. In some cycles it may also inhibit ovulation, together preventing fertilisation and implantation.

Kyleena contains a total of 19.5 mg of levonorgestrel that is released continuously over a period of up to five years. The specific dosing regimen, including timing of insertion and follow‑up, is determined by the prescribing clinician based on the patient’s medical history and contraceptive needs.

Kyleena is contraindicated in women who are pregnant; it must be removed if pregnancy occurs. Limited data are available for use during breastfeeding, and most guidelines recommend postponing insertion until after the postpartum period and after lactation has been established, unless a clinician determines it is appropriate.

To order Kyleena, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets, and will request verification of trade or institutional credentials. The sales team then replies with pricing, availability, shipping details and any required import documentation.

The primary alternative intrauterine system is Mirena, which contains 52 mg of levonorgestrel and is approved for up to five years of use. Kyleena delivers a lower total hormone dose (19.5 mg), which may result in fewer hormonal side effects for some users while providing comparable contraceptive efficacy. Choice depends on individual patient factors and clinician judgment.

Kyleena should be stored at room temperature, below 25 °C, in its original sealed packaging. Protect the device from moisture, direct sunlight and extreme temperatures. Handling should be performed by trained healthcare professionals using aseptic technique during insertion, and the packaging should remain intact until the time of use.

Kyleena is inserted by a qualified healthcare provider into the uterine cavity using a specialized applicator. The procedure is performed in a clinical setting under sterile conditions. Once placed, the device releases levonorgestrel continuously; no further dosing is required until removal or replacement, typically after up to five years.

Serious risks associated with Kyleena include uterine perforation during insertion, device expulsion, ectopic pregnancy if contraception fails, and pelvic inflammatory infection. Patients should be instructed to seek immediate medical attention if they experience severe abdominal pain, abnormal bleeding, fever, or signs of infection following insertion.

Kyleena is contraindicated in women who are currently pregnant, have active pelvic infection, unexplained vaginal bleeding, known or suspected uterine anomalies (e.g., bicornuate uterus), untreated cervical cancer, or a history of breast cancer or severe liver disease. It should also be avoided in individuals with known hypersensitivity to levonorgestrel or any component of the device.